{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.27","upperLimit":"85.34","value":"40.0"},{"groupId":"OG001","lowerLimit":"0.63","upperLimit":"80.59","value":"25.0"},{"groupId":"OG002","lowerLimit":"33.06","upperLimit":"69.85","value":"51.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"31"}],"units":"Participants"}],"description":"Overall tumor response is the sum of a complete response (CR), very good partial response (VGPR), partial response (PR) and minimal response (MR). A modified version of the Bladé criteria for response was used. Abbreviated definitions for the response categories can be found in the description of outcome #3.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bortezomib 1.0 mg/m\\^2/dose (days 1, 4, 8 and 11) by intravenous push and Bendamustine 50 mg/m\\^2/dose (days 1 and 4) intravenously for up to eight 28 day cycles.","id":"OG000","title":"Bendamustine 50 mg/m^2 Cohort"},{"description":"Bortezomib 1.0 mg/m\\^2/dose (days 1, 4, 8 and 11) by intravenous push and Bendamustine 70 mg/m\\^2/dose (days 1 and 4) intravenously for up to eight 28 day cycles.","id":"OG001","title":"Bendamustine 70 mg/m^2 Cohort"},{"description":"Bortezomib 1.0 mg/m\\^2/dose (days 1, 4, 8 and 11) by intravenous push and Bendamustine 90 mg/m\\^2/dose (days 1 and 4) intravenously for up to eight 28 day cycles.","id":"OG002","title":"Bendamustine 90 mg/m^2 Cohort"}],"paramType":"NUMBER","populationDescription":"Efficacy population","reportingStatus":"POSTED","timeFrame":"Up to 7.5 months (eight 28-day cycles)","title":"Percentage of Participants With An Overall Tumor Response As Assessed By the Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}